These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15748956)

  • 1. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
    Graber J; Zhan M; Ford D; Kursch F; Francis G; Bever C; Panitch H; Calabresi PA; Dhib-Jalbut S
    J Neuroimmunol; 2005 Apr; 161(1-2):169-76. PubMed ID: 15748956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
    Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J; Francis G; Chang P;
    J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
    Jensen J; Krakauer M; Sellebjerg F
    Cytokine; 2005 Jan; 29(1):24-30. PubMed ID: 15579375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
    Di Rezze S; Gupta S; Durastanti V; Millefiorini E; Pozzilli C; Bagnato F
    Mult Scler; 2007 Apr; 13(3):343-7. PubMed ID: 17439903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon inhibitory activity in patients with multiple sclerosis.
    Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
    Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.